



ISSN 0975-413X
CODEN (USA): PCHHAX

Der Pharma Chemica, 2016, 8(18):242-254
(<http://derpharmachemica.com/archive.html>)

Study of genetic variations of *FTO* gene and its relationship to obese in Iraqi population

Mustafa N. Jumaa¹, Nahi Y. Yaseen², Rafid M. Karim³, Adil F. Shehab⁴
and Likaa H. Sagban⁵

¹Department of Biology, College of Science, Al-Anbar University,

²Iraqi Center for Cancer and Medical Genetic Research, Al-Mustansiryia University,

³Marine Science Centre, Basrah University,

⁴Department of Biology, College of Science, Tikrit University,

⁵Department of Biology, College of Education, Karbala University

ABSTRACT

This study included 120 of obese males with mean age 20-50 year and 50 aged-matched healthy males as a control. The obese patients classified into 3 groups based on Body Mass Index (BMI). DNA was isolated from the collected blood samples and applied for PCR using primers designed for exons 3 and 9 of FTO gene. The results showed that there are 8 mutations in the exon 3. Seven of the mutations are transition and one is transversion. Furthermore, seven of which are predicted to be missense and one is silent. As for exon 9, twelve mutations were identified. Eight of the mutations are transversion and 4 are transition, whereas eleven of which are predicted to be missense and one is silent. The mutations in both 3 and 9 exons recorded a significant differences ($p \leq 0.05$) with a Chi-square (X^2) 63.229 and 24.802 respectively in the incidence of the pathogenicity comparison to the control.

INTRODUCTION

Obesity became a threat that rapidly growing to adversely effects on the health of populations in many of countries. Obesity associated diseases include hypertension, pulmonary diseases, coronary heart disease, diabetes type 2, gallbladder disease, cancer, etc [1]. Body overweight is the sixth risk factor that causes overall onus of disease all over the world [2]. Also, the fifth leading risk for global deaths comes from overweight and obesity. Each year there is at least 2.8 million adults die as a result of body overweight or obese. More than 1.4 billion adults, according to the WHO in 2008, were overweight. Over 200 and 300 million of these were men and women obese respectively. 44%, 23% and 7- 41 % of diabetes, ischaemic heart disease and certain cancer burdens are attributed to body overweight and obesity [2, 3, and 4]. The gene fat mass and obesity-associated (*FTO*) located on chromosome 16 (16q12.2) and encoded for an enzyme known as alpha-ketoglutarate-dependent dioxygenase which repairs alkylated RNA and DNA through oxidative demethylation of single-stranded RNA and DNA containing 3-methyluracil and 3-methylthimine respectively [5, 6, 7 and 8]. The enzyme specifically demethylates N6-methyladenosine (m6A) RNA, the most common modification of mRNA in eukaryote. Human hypothalamus highly expressed for *FTO*. Also, it expressed by pituitary and adrenal glands which indicates a potential role for *FTO* gene in the regulation of body weight [9]. Mutation in *FTO* associated with increased obesity and type 2 diabetes risk factors, which reflect the importance of m6A in physiological pathways involving in human diseases [10]. The *FTO* contributes in

regulation of metabolic rate, body fat accumulation, energy expenditure and participates in regulation of thermogenesis and differentiation of adipocytes [5, 6 and 11]. Boissel et al [12] generated mice have temporal and spatial lack for *FTO* expression that resulted in a reduction in body length, weight, fat mass and lean mass. A high fat dietary in mice causes a high expression of *FTO* which contributes in pathogenesis of non-alcoholic fatty liver disease [13]. Huang et al [14] identified a selective inhibitor called meclofenamic acid (AM) which compete m6A substrate for binding to *FTO*, the work that highlighted on the development of epigenetic processes for drug discovery of obesity. Deficiency in *FTO* is effective in protection from development of obesity and metabolic syndrome [15]. Study by Walter et al [16] revealed that genes involving in obesity, especially *FTO*, may directly effect on phobic anxiety which indicated that obesity and phobic anxiety shared common genetic determinants. Two neighboring genes, *RPGRIP1L* and *IRX3*, of *FTO* have been implicated in the obesity associated with *FTO*. Disturbance in expression of these genes resulted in a smaller mice and mild obesity [17]. Zhao et al [18] showed that the exonic splicing of adipogenic regulatory factor *RUNX1T1* controlled by *FTO* through regulating levels of m6A around splice sites and thus the *FTO*-dependent m6A demethylation plays an important role in the adipogenesis regulation. Obesity related to carrier of risk allele *FTO* gene showed increased in body mass during aging. In addition to, reduced in brain function including impulse control and taste responsiveness, and increased impulsivity and fatty food intake [19].

MATERIALS AND METHODS

Sampling

Four ml of blood samples for genetic analysis were collected from 170 men who their ages range from 20-50 years, 120 of them are obese who were classified based on *BMI* into three groups. Obesity group I (*BMI*= 30-34.9), obesity group II (*BMI*= 35-39.9) and obesity group III (*BMI*= 40 onwards). Other men (50) are apparently healthy and they were grouped as a control (*BMI*= 18-24.9).

Body Measurements

For *BMI*, weight dividing by height square (Kilogram/ meter²) was determined. The central obesity (*CO*) calculated by the ratio of the waist circumference to the Hip circumference.

Extraction of DNA

DNA isolation kit from Geneaid was used to extract DNA from blood samples and based on the procedure provided by manufacturer.

Amplifying of exons 3 and 9 of *FTO* gene

Forward primers (5'- CAC TCC GGT ATC TCG CAT CC -3') and (5'- CTA TGC TCA GCA CAC GGG AA -3') were used to amplify the exons 3 and 9 respectively. While revers primers (5'- ACA ATG GCA CAG CAT CCT CA -3') and (5'- AGC CAG GTC AGA AAG GGA GA -3') were used to amplify the exons 3 and 9 respectively. All the primers were obtained from Integrated DNA Technologies Company (USA). The PCR reaction mixture with a final volume 25 μ l included 2 μ l of 100 ng/ μ l DNA, 12.5 μ l of GoTaq® Green Master Mix 2X (Promega Company, USA) and 10.5 μ l of nucleases free water. Cycling condition of PCR was shown in table (1). Agarose gel (1.5 %) was then run for the products of the PCR reaction mixtures.

Table 1: PCR cycling condition

PCR cycling condition for exon 3			
Cycle step	Temp.	Time	Cycle No.
Initial denaturation	94 °C	5 min	1
Denaturation	94 °C	45 sec	35
Annealing	64 °C	53 sec	
Extension	72 °C	45 sec	
Final extension	72 °C	7 min	1
PCR cycling condition for exon 9			
Cycle step	Temp.	Time	Cycle No.
Initial denaturation	94 °C	5 min	1
Denaturation	94 °C	45 sec	30
Annealing	62 °C	35 sec	
Extension	72 °C	45 sec	
Final extension	72 °C	7 min	1

Nucleic acids analysis

60 samples with 20 μ l of the PCR product, 40 samples selected randomly from all obese groups and 20 samples selected randomly from control, were sent to Micro gen company (USA) to check the DNA sequencing of exons 3 and 9 of *FTO* gene. The obtained results were then compared with the published sequence on the National Center of Biotechnology Information (NCBI).

Statistics Analysis

Chi-Square (X^2 Test) was used to assess the significant differences ($P \leq 0.05$) between different factors in the current study.

RESULTS

The relationship between *BMI* and *CO* was shown in figure (1), the *CO* was increased by increasing in *BMI*. Also, it has found significant differences in *BMI* between control and obesity groups as well as among the three groups of obesity themselves (figure 2-A and table 2). Significant differences in *CO* were noticed between control and obesity groups. In contrast, there are no significant differences in *CO* showed among the three groups of obesity (figure 2-B). Bands of a predicted lengths 239 and 559 bp were resulted from analysis of PCR products of exons 3 and 9 of *FTO* gene on agarose gels respectively (figures 3 and 4). Results of nucleic acids alignments for *FTO* exon-3 and *FTO* exon-9 of control groups, by using NCBI, showed 99% and 100% identities respectively (figures 5 and 7).

BLASTN of *FTO* exon-3 of (40) obese men showed many of mutations in nucleotides bases. There were (4) samples have G127265A mutation (transition) resulted in an alteration from Alanine to Threonine (figure 6-A, table 3). Also, twenty eight samples have A127156G and A127160G mutations (transitions) resulted in a silent mutation in the first location and missense mutation in the second location (figure 6-B, table 3). While there were (36) samples have A127158G and C127159T mutations caused an alteration from Histidine to Arginine in both locations (figure 6-B, figure 6-C, table 3). Furthermore, eight samples showed A127154G and A127156G mutations lead to Lysine to Glutamic acid missense mutations (figure 6-C, table 3). On the other hand, A127171T mutation has been noticed in all samples of obese men caused Glutamic acid to Aspartic acid missense mutation (figure 6, A to C).

As for *FTO* exon-9, BLASTN of (40) obese men showed (16) samples have T413837A mutation resulted in isoleucine to asparagine alteration (figure 8-A, table 4). Ten samples were carried T413837A and T413838A mutations caused isoleucine to lysine alteration (figure 8-B and C, table 4). Also, there were (4) samples have A413833C, C414194T and A414199T mutations which resulted in alterations in isoleucine to leucine, threonine to isoleucine and methionine to leucine respectively (figure 8-B, table 4). Six samples were carried T413834G, G413841A, T413842G and G413878T mutations lead to alteration in isoleucine to Serine, serine to serine (silent), tryptophan to glycine and lysine to asparagine (figure 8-C, table 4). Moreover, it has found (14) samples having A413776G and A413778G mutations caused isoleucine to valine alteration (figure 8-D, table 4).

Statistical analysis revealed that all the mutations recorded in the exons 3 and 9 of *FTO* gene of obese men were effective in the occurrence of the disease ($p \leq 0.05$) with X^2 63.229 and X^2 24.802 respectively.




Figure 1: relationship between *BMI* and *CO*




Figure 2: BMI (A) and CO (B) among obesity and control groups

Table 2: Sorting of samples depending on BMI (A) and CO (B)

Group	BMI (kg/m2)	Global BMI (kg/m2)	No. of samples	CO
Control	23.76	18-24.9	50	0.95
Group I obesity	33.31	30-34.9	30	1.49
Group II obesity	37.95	35-39.9	40	1.54
Group III obesity	49.76	40 onwards	50	1.58




Figure 3: Analysis of exon 3 of FTO gene on 1.5 % agarose gel electrophoresis. The gel was run for one hour and half at 100 volts. M: 100 bp DNA ladder; Lane N: Control (healthy); Lanes 1-8: Patients (obese men)



Figure 4: Analysis of exon 9 of FTO gene on 1.5 % agarose gel electrophoresis. The gel was run for one hour and half at 100 volts. M: 50 bp DNA ladder; Lane N: Control (healthy); Lanes 1-12: Patients (obese men)

Table 3: Nucleotides alteration and a concomitant alteration of amino acids in exon 3 of *FTO* gene in obese men

Replication of Mutation	location of gene bank	Nucleotide change	Amino acid change	Predicted effect	Type of mutation
4	G127265A	GCT/ACT	Alanine/Threonine	Missense	Transition
28	A127156G	AAA/AAG	Lysine/Lysine	Silent	Transition
36	A127158G	CAC/CGT	Histidine/Arginine	Missense	Transition
36	C127159T	CAC/CGT	Histidine/Arginine	Missense	Transition
28	A127160G	ACC/GCC	Threonine/Alanine	Missense	Transition
8	A127154G	AAA/GAG	Lysine/Glutamic acid	Missense	Transition
8	A127156G	AAA/GAG	Lysine/Glutamic acid	Missense	Transition
40	A127171T	GAA/GAT	Glutamic acid/Aspartic acid	Missense	Transversion

Table 4: Nucleotides alteration and a concomitant alteration of amino acids in exon 9 of *FTO* gene in obese men

Replication of Mutation	location of gene bank	Nucleotide change	Amino acid change	Predicted effect	Type of mutation
16	T413837A	ATT/AAT	Isoleucine/Asparagine	Missense	Transversion
10	T413837A	ATT/AAA	Isoleucine/Lysine	Missense	Transversion
10	T413838A	ATT/AAA	Isoleucine/Lysine	Missense	Transversion
4	A413833C	ATT/CTT	Isoleucine/Leucine	Missense	Transversion
4	C414194T	ACC/ATC	Threonine/ Isoleucine	Missense	Transition
4	A414199T	ATG/TTG	Methionine/Leucine	Missense	Transversion
6	T413834G	ATT/AGT	Isoleucine/Serine	Missense	Transversion
6	G413841A	TCC/TCA	Serine/Serine	Silent	Transition
6	T413842G	TGG/GGG	Tryptophan/Glycine	Missense	Transversion
6	G413878T	AAG/AAT	Lysine/Asparagine	Missense	Transversion
14	A413776G	ATA/GTG	Isoleucine/Valine	Missense	Transition
14	A413778G	ATA/GTG	Isoleucine/Valine	Missense	Transition

Homo sapiens fat mass and obesity associated (*FTO*),

RefSeqGene on chromosome 16

Sequence ID: [refNG_012969.1](#) Length: 417505 Number of Matches: 1

Score: 235 bits(127) **Expect:** 1e-58 **Identities:** 129/130(99%) **Gaps:** 0/130(0%) **Strand:** Plus/Plus

Query 62 ACCGAGGCTGAAATAGCCGCTGCTTGTGAGACCTTCCTCAAGCTCAATGACTACCTGCAG
121

|||||

Sbjct 127160

ACCGAGGCTGAAATAGCCGCTGCTTGTGAGACCTTCCTCAAGCTCAATGACTACCTGCAG 127219

Query 122

ATAGAAACCATCCAGGCTTTGGAAGAAGCTTGCTGCCAAAGAGAAGGCTAATGAGGATGCT 181

|||||

Sbjct 127220

ATAGAAACCATCCAGGCTTTGGAAGAAGCTTGCTGCCAAAGAGAAGGCTAATGAGGATGCT 127279

Query 182 GTGCCATTGT 191

|||||

Sbjct 127280 GTGCCATTGT 127289

Figure 5: Nucleic acids alignment of *FTO* exon -3 of (20) control healthy men (Query) with standard sequence (subject) by using NCBI

(A)

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [refNG_012969.1](#) Length: 417505 Number of Matches: 1

Score: 240 bits(121) Expect: 4e-60 Identities: 127/129(98%) Gaps: 0/129(0%) Strand: Plus/Plus

Query 61 CCGAGGCTGATATAGCCGCTGCTTGTGAGACCTTCCTCAAGCTCAATGACTACCTGCAGA 120

||||| |

Sbjct 127161

CCGAGGCTGATAATAGCCGCTGCTTGTGAGACCTTCCTCAAGCTCAATGACTACCTGCAGA 127220

Query 121

TAGAAACCATCCAGGCTTTGGAAGAAGCTTGTGCCAAAGAGAAGACTAATGAGGATGCTG 180

||||| |

Sbjct 127221

TAGAAACCATCCAGGCTTTGGAAGAAGCTTGTGCCAAAGAGAAGACTAATGAGGATGCTG 127280

Query 181 TGCCATTGT 189

|||||

Sbjct 127281 TGCCATTGT 127289

(B)

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [refNG_012969.1](#) Length: 417505 Number of Matches: 1

Score: 248 bits(134) Expect: 1e-62 Identities: 144/149(97%) Gaps: 0/149(0%) Strand: Plus/Plus

Query 42 AGGGTCTAATATAAAGCGTCCGAGGCTGATATAGCCGCTGCTTGTGAGACCTTCCTCAA 101

||||| |

Sbjct 127141

AGGGTCTAATATAAAGACACCGAGGCTGATAATAGCCGCTGCTTGTGAGACCTTCCTCAA 127200

Query 102

GCTCAATGACTACCTGCAGATAGAAACCATCCAGGCTTTGGAAGAAGCTTGTGCCAAAGA 161

||||| |

Sbjct 127201

GCTCAATGACTACCTGCAGATAGAAACCATCCAGGCTTTGGAAGAAGCTTGTGCCAAAGA 127260

Query 162 GAAGGCTAATGAGGATGCTGTGCCATTGT 190

|||||

Sbjct 127261 GAAGGCTAATGAGGATGCTGTGCCATTGT 127289

(C)

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [ref|NG_012969.1](#) Length: 417505 Number of Matches: 1

Score: 241 bits(130) **Expect:** 2e-60 **Identities:** 142/148(96%) **Gaps:** 0/148(0%) **Strand:** Plus/Plus

Query 43 gggTCTAATATAGAGCGTGCCGAGGCTGATATAGCCGCTGCTTGTGAGACCTTCCTCAAG
102

||||||| | | ||||||| |||||||||||||||||||

Sbjct 127142

GGGTCTAATATAAACACAACCGAGGCTGAAATAGCCGCTGCTTGTGAGACCTTCCTCAAG 127201

Query 103

CTCAATGACTACCTGCAGATAGAAACCATCCAGGCTTTGGAAGAAGCTTGCTGCCAAAGAG 162

|||||||||||||||||||||||||||||||||

Sbjct 127202

CTCAATGACTACCTGCAGATAGAAACCATCCAGGCTTTGGAAGAAGCTTGCTGCCAAAGAG 127261

Query 163 AAGGCTAATGAGGATGCTGTGCCATTGT 190

|||||||||||||||||

Sbjct 127262 AAGGCTAATGAGGATGCTGTGCCATTGT 127289

Figure (6): Nucleic acids alignment of *FTO* exon -3 of (40) obese men (Query) with standard sequence (subject) by using NCBI. (A): alignment for 4 samples; (B): alignment for 28 samples; (C): alignment for 8 samples

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [ref|NG_012969.1](#) Length: 417505 Number of Matches: 1

Score: 935 bits (506) **Expect:** 0.0 **Identities:** 506/506(100%) **Gaps:** 0/506(0%) **Strand:** Plus/Plus

Query 25 CTGTCTTTAGGGAGTTCCTTGATCTCTTGAAAGAGACACAGCCCCATTTACATTATTTTC
84

|||||||||||||||||||||||||||||||||

Sbjct 413781 CTGTCTTTAGGGAGTTCCTTGATCTCTTGAAAGAGACACAGCCCCATTTACATTATTTTC
413840

Query 85 GTGGATTTACACCAGCATAGTATAGTTTTCTGTAAGTCCCTCATTCTTATGTAATAAC 144

|||||||||||||||||||||||||||||||||

Sbjct 413841 GTGGATTTACACCAGCATAGTATAGTTTTCTGTAAGTCCCTCATTCTTATGTAATAAC
413900

Query 145

AGGTGGAAGTGGAGTTTGAAGAACCTCAGTGGCCCATCCTGATGACATTGGAGACTCAA 204

|||||||||||||||||||||||||||||||||

Sbjct 413901

AGGTGGAAGTGGAGTTTGAAGAACCTCAGTGGCCCATCCTGATGACATTGGAGACTCAA 413960

Query 205

GAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTTAAGACTCCCCTAGCTTCGTGTCC 264

|||||||||||||||||||||||||||||||||

Sbjct 413961

GAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTTAAGACTCCCCTAGCTTCGTGTCC 414020

Query 265 TTTGGCATGTTAACGTGCCTCAGTTTCCTCATCTGTATAATGGGGATATATGAAAGGCAC
324

|||||
 Sbjct 414021 TTTGGCATGTAAACGTGCCTCAGTTTCCTCATCTGTATAATGGGGATATATGAAAGGCAC
 414080

Query 325 CAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAGTTACAGACTTAGAACAATTTCCAG
 384

|||||
 Sbjct 414081
 CAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAGTTACAGACTTAGAACAATTTCCAG 414140

Query 385 CACATAGTTAAATATCCAGGAAATTCTGGTACTGTTATGTGTGGGTGAGCTGACCTGGAT
 444

|||||
 Sbjct 414141 CACATAGTTAAATATCCAGGAAATTCTGGTACTGTTATGTGTGGGTGAGCTGACCTGGAT
 414200

Query 445 GTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCCAGTTTTGTCTTGTGATGCCATTAA
 504

|||||
 Sbjct 414201 GTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCCAGTTTTGTCTTGTGATGCCATTAA
 414260

Query 505 CACATCTCTCCCTTTCTGACCTGGCT 530

|||||
 Sbjct 414261 CACATCTCTCCCTTTCTGACCTGGCT 414286

Figure 7: Nucleic acids alignment of *FTO* exon-9 of (20) control healthy men (Query) with standard sequence (sbjct) by using NCBI

(A)
 Homo sapiens fat mass and obesity associated (FTO)
 RefSeqGene on chromosome 16
 Sequence ID: [refNG_012969.1](https://www.ncbi.nlm.nih.gov/nuccore/012969.1) Length: 417505 Number of Matches: 1
Score: 863 bits(467) **Expect:** 0.0 **Identities:** 469/470(99%) **Gaps:** 0/470(0%) **Strand:** Plus/Plus

Query 1 ACACAGCCCCATTTACATTAATTCGTGGATTTCACCAGCATAGTATAGTTTTCTGTA 60
 |||||
 Sbjct 413817 ACACAGCCCCATTTACATTAATTCGTGGATTTCACCAGCATAGTATAGTTTTCTGTA
 413876

Query 61 AGTCCCTCATTCTTATGTAATAACAGGTGGAAGTGGAGTTTGAAGAACCTCAGTGGCCCA
 120

|||||
 Sbjct 413877
 AGTCCCTCATTCTTATGTAATAACAGGTGGAAGTGGAGTTTGAAGAACCTCAGTGGCCCA 413936

Query 121 TCCTGATGACATTGGAGACTCAAAGAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTT 180

|||||
 Sbjct 413937
 TCCTGATGACATTGGAGACTCAAAGAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTT 413996

Query 181 AAGACTCCCAGTCTTCGTGTCCTTTGGCATGTAAACGTGCCTCAGTTTCCTCATCTGT
 240

|||||
 Sbjct 413997 AAGACTCCCAGTCTTCGTGTCCTTTGGCATGTAAACGTGCCTCAGTTTCCTCATCTGT
 414056

Query 241

ATAATGGGGATATATGAAAGGCACCAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAG 300

Sbjct 414057

ATAATGGGGATATATGAAAGGCACCAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAG 414116

Query 301 TTACAGACTTAGAACAATTTCCAGCACATAGTTAAATATCCAGGAAATTCTGGTACTGTT
360Sbjct 414117 TTACAGACTTAGAACAATTTCCAGCACATAGTTAAATATCCAGGAAATTCTGGTACTGTT
414176Query 361 ATGTGTGGGTGAGCTGACCTGGATGTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCC
420Sbjct 414177 ATGTGTGGGTGAGCTGACCTGGATGTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCC
414236

Query 421 AGTTTTGTCTTGTGATGCCATTAACACATCTCTCCCTTTCTGACCTGGCT 470

Sbjct 414237 AGTTTTGTCTTGTGATGCCATTAACACATCTCTCCCTTTCTGACCTGGCT 414286

(B)

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [refNG_012969.1](#) Length: 417505 Number of Matches: 1**Score:** 870 bits(471) **Expect:** 0.0 **Identities:** 485/492(99%) **Gaps:** 0/492(0%) **Strand:** Plus/PlusQuery 42 TTCCTTGATCTCTGAAAGAGACACAGCCCCATTTACCTTAAATCGTGGATTTACCAG
101Sbjct 413795 TTCCTTGATCTCTGAAAGAGACACAGCCCCATTTACCTTAAATCGTGGATTTACCAG
413854

Query 102 CATAGTATAGTTTTCTGTACTTCCCTCATTCTTATGTAATAACAGGTGGAAGTGGAGG 161

Sbjct 413855 CATAGTATAGTTTTCTGTAACTCCCTCATTCTTATGTAATAACAGGTGGAAGTGGAGG
413914

Query 162

TTTGAAGAACCTCAGTGGCCCATCCTGATGACATTGGAGACTCAAAGAGACAAGAGAGAG 221

Sbjct 413915

TTTGAAGAACCTCAGTGGCCCATCCTGATGACATTGGAGACTCAAAGAGACAAGAGAGAG 413974

Query 222 TAGGGTTTAAAACCTGAGCTTTAAGACTCCCACTAGCTTCGTGTCCTTTGGCATGTAAAC
281Sbjct 413975 TAGGGTTTAAAACCTGAGCTTTAAGACTCCCACTAGCTTCGTGTCCTTTGGCATGTAAAC
414034Query 282 GTGCCTCAGTTTCCTCATCTGTATAATGGGGATATATGAAAGGCACCAGTCCTAAGGTGA
341

Sbjct 414035

GTGCCTCAGTTTCCTCATCTGTATAATGGGGATATATGAAAGGCACCAGTCCTAAGGTGA 414094

Query 342 ACATTAAGTGAGATGATTCTAGTTACAGACTTAGAACAAATTTCCAGCACATAGTTAAATA
401

|||||
Sbjct 414095
ACATTAAGTGAGATGATTCTAGTTACAGACTTAGAACAAATTTCCAGCACATAGTTAAATA 414154

Query 402 TCCAGGAAATTCTGGTACTGTTATGTGTGGGTGAGCTGACTGGTTGTAGATGTTTTCCT
461

||||| ||| |||
Sbjct 414155 TCCAGGAAATTCTGGTACTGTTATGTGTGGGTGAGCTGACTGGATTGTAGATGTTTTCCT
414214

Query 462 CTCTCTTGCTGACCCCTCCGCCAGTTTTGTCTTGTGATGCCATTAACACATCTCTCCCTT
521

|||||
Sbjct 414215 CTCTCTTGCTGACCCCTCCGCCAGTTTTGTCTTGTGATGCCATTAACACATCTCTCCCTT
414274

Query 522 TCTGACCTGGCT 533

|||||
Sbjct 414275 TCTGACCTGGCT 414286

(C)

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [refNG_012969.1](#) Length: 417505 Number of Matches: 1

Score: 830 bits(449) Expect: 0.0 Identities: 461/467(99%) Gaps: 0/467(0%) Strand: Plus/Plus

Query 1 CAGCCCCATTTACAGTAAATCAGGGATTCACCAGCATAGTATAGTTTTCTGTAAAT 60

||||| || |||
Sbjct 413820 CAGCCCCATTTACATTAATTCAGGGATTCACCAGCATAGTATAGTTTTTTCTGTAAAGT
413879

Query 61 CCCTCATTCTTATGTAATAACAGGTGGAAGTGGAGTTTGAAGAACCTCAGTGGCCCATCC
120

|||||
Sbjct 413880 CCCTCATTCTTATGTAATAACAGGTGGAAGTGGAGTTTGAAGAACCTCAGTGGCCCATCC
413939

Query 121 TGATGACATTGGAGACTCAAAGAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTTAAG 180

|||||
Sbjct 413940 TGATGACATTGGAGACTCAAAGAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTTAAG 413999

Query 181 ACTCCCACTAGCTTCGTGTCCTTTGGCATGTTAACGTGCCTCAGTTTCCTCATCTGTATA
240

|||||
Sbjct 414000 ACTCCCACTAGCTTCGTGTCCTTTGGCATGTTAACGTGCCTCAGTTTCCTCATCTGTATA
414059

Query 241 ATGGGGATATATGAAAGGCACCAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAGTTA 300

|||||

Sbjct 414060

ATGGGGATATATGAAAGGCACCAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAGTTA 414119

Query 301 CAGACTTAGAACAATTTCCAGCACATAGTTAAATATCCAGGAAATTCTGGTACTGTTATG
360

|||||

Sbjct 414120 CAGACTTAGAACAATTTCCAGCACATAGTTAAATATCCAGGAAATTCTGGTACTGTTATG
414179Query 361 TGTGGGTGAGCTGACCTGGATGTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCCAGT
420

|||||

Sbjct 414180 TGTGGGTGAGCTGACCTGGATGTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCCAGT
414239

Query 421 TTTGTCTTGTGATGCCATTAACACATCTCTCCCTTTCTGACCTGGCT 467

|||||

Sbjct 414240 TTTGTCTTGTGATGCCATTAACACATCTCTCCCTTTCTGACCTGGCT 414286

(D)

Homo sapiens fat mass and obesity associated (FTO)

RefSeqGene on chromosome 16

Sequence ID: [refNG_012969.1](#) Length: 417505 Number of Matches: 1**Score:** 939 bits(508) **Expect:** 0.0 **Identities:** 512/514(99%) **Gaps:** 0/514(0%) **Strand:** Plus/PlusQuery 16 GTTGCTGTCCTGTCTTTAGGGAGTTCCTTGATCTCTTGAAAGAGACACAGCCCCATTTA
75

||| |

Sbjct 413772 GTTGCTGTCCTGTCTTTAGGGAGTTCCTTGATCTCTTGAAAGAGACACAGCCCCATTTA
413831

Query 76 CATTATTTTCGTGGATTTACCAGCATAGTATAGTTTTCTGTAAGTCCCTCATTCTTA 135

|||||

Sbjct 413832 CATTATTTTCGTGGATTTACCAGCATAGTATAGTTTTCTGTAAGTCCCTCATTCTTA
413891

Query 136

TGTAATAACAGGTGGAACCTGAGGTTTGAAGAACCTCAGTGGCCCATCCTGATGACATTGG 195

|||||

Sbjct 413892

TGTAATAACAGGTGGAACCTGAGGTTTGAAGAACCTCAGTGGCCCATCCTGATGACATTGG 413951

Query 196

AGACTCAAAGAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTTAAGACTCCCACTAGC 255

|||||

Sbjct 413952

AGACTCAAAGAGACAAGAGAGAGTAGGGTTTAAAACCTGAGCTTTAAGACTCCCACTAGC 414011

Query 256 TTCGTGTCCTTTGGCATGTTAACGTGCCTCAGTTTCCTCATCTGTATAATGGGGATATAT
315

|||||

Sbjct 414012 TTCGTGTCCTTTGGCATGTTAACGTGCCTCAGTTTCCTCATCTGTATAATGGGGATATAT
414071

Query 316

GAAAGGCACCAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAGTTACAGACTTAGAAC 375

```

|||||
Sbjct 414072
GAAAGGCACCAGTCCTAAGGTGAACATTAAGTGAGATGATTCTAGTTACAGACTTAGAAC 414131

Query 376  AATTTCCAGCACATAGTTAAATATCCAGGAAATTCTGGTACTGTTATGTGTGGGTGAGCT
435
|||||
Sbjct 414132  AATTTCCAGCACATAGTTAAATATCCAGGAAATTCTGGTACTGTTATGTGTGGGTGAGCT
414191

Query 436  GACCTGGATGTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCCAGTTTTGTCTTGTGA
495
|||||
Sbjct 414192  GACCTGGATGTAGATGTTTTCTCTCTCTTGCTGACCCCTCCGCCAGTTTTGTCTTGTGA
414251

Query 496  TGCCATTAACACATCTCTCCCTTTCTGACCTGGC 529
|||||
Sbjct 414252  TGCCATTAACACATCTCTCCCTTTCTGACCTGGC 414285

```

Figure (8): Nucleic acids alignment of *FTO* exon-9 of (40) obese men (Query) with standard sequence (subject) by using NCBI. (A): alignment for 3 samples; (B): alignment for 4 samples; (C): alignment for 6 samples; (D): alignment for 14 samples

DISCUSSION

Eight mutations in the *FTO* exon-3 has been indicated in this study, most of them (7) are missense and only one was silent (table 3, figure 6). On the other hand, 12 mutations were identified in the *FTO* exon-9, 11 of which are missense and one was silent (table 4, figure 8). In a similar study by Fan et al [20], they showed that mutations in the exon 3 of the *FTO* gene were associated with increasing of intramuscular fat and growth rate in pig. Also, Church et al [21] showed that a single mutation in the *FTO* exon-6 of mice decreased functional activity of FTO resulted in a reduction in fat mass and body weight. Furthermore, Meyre et al [22], they scanned all exons of the *FTO* gene, identified 18 and 6 nonsynonymous (missense) mutations in the exons 3 and 9 of the *FTO* gene of Europeans obese respectively in addition to 11 other nonsynonymous mutations in the rest of the *FTO* exons. And they showed that these mutations associated with FTO function. The function of the FTO could impacts on energy balance. Mice null for *FTO* are lean and have increasing in metabolic rate, while mice with *FTO*^{+/-} genotype were resistant to diet induced obesity [23]. Based on findings of the present study we can concluded that the mutations that found in the exons 3 and 9 of *FTO* could influence on FTO function, resulted in an increasing in FTO function, which brought about the obesity.

REFERENCES

- [1] World Health Organization. Obesity: preventing and managing the global epidemic. *World Health Organization*; **2000**.
- [2] DW Haslam, James WP. *Lancet*. **2005**;366(9492):1197–209.
- [3] World Health Organization. Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation, Geneva, **2008** Dec. 8-11.
- [4] S Gutterman. Obesity: Status and Effects. *Living to*. **2011** Jan 5;100.
- [5] G Jia, CG Yang, S Yang, X Jian, C Yi, Z Zhou, C He. *FEBS letters*. **2008** Oct 15;582(23-24):3313-9.
- [6] Z Han, T Niu, J Chang, X Lei, M Zhao, Q Wang, W Cheng, J Wang, Y Feng, J Chai. *Nature*. **2010** Apr 22;464(7292):1205-9.
- [7] G Jia, Y Fu, X Zhao, Q Dai, G Zheng, Y Yang, C Yi, T Lindahl, T Pan, YG Yang, C He. *Nature chemical biology*. **2011** Dec 1;7(12):885-7.
- [8] J Zhou, J Wan, X Gao, X Zhang, SR Jaffrey, SB Qian. *Nature*. **2015** Oct 22;526(7574):591-4.
- [9] A López-Bermejo, CJ Petry, M Díaz, G Sebastiani, F de Zegher, DB Dunger, L Ibáñez. *The Journal of Clinical Endocrinology & Metabolism*. **2008** Apr;93(4):1501-5.

- [10] D Dominissini, S Moshitch-Moshkovitz, S Schwartz, M Salmon-Divon, L Ungar, S Osenberg, K Cesarkas, J Jacob-Hirsch, N Amariglio, M Kupiec, R Sorek. *Nature*. **2012** May 10;485(7397):201-6.
- [11] M Claussnitzer, SN Dankel, KH Kim, G Quon, W Meuleman, C Haugen, V Glunk, IS Sousa, JL Beaudry, V Puvion-Rand, NA Abdennur. *N Engl J Med*. **2015** Sep 3;2015(373):895-907.
- [12] S Boissel, O Reish, K Proulx, H Kawagoe-Takaki, B Sedgwick, GS Yeo, D Meyre, C Golzio, F Molinari, N Kadhom, HC Etchevers. *The American Journal of Human Genetics*. **2009** Jul 10;85(1):106-11.
- [13] J Zhang, S Li, J Li, C Han, Z Wang, C Li, X Wang, Z Liu, J Wen, L Zheng. *Chinese medical journal*. **2014** Nov;127(21):3771-6.
- [14] Y Huang, J Yan, Q Li, J Li, S Gong, H Zhou, J Gan, H Jiang, GF Jia, C Luo, CG Yang. *Nucleic acids research*. **2014** Dec 1;gku1276.
- [15] K Ikels, S Kuschel, J Fischer, W Kaisers, D Eberhard, U Rüther. *PloS one*. **2014** Aug 21;9(8):e105349.
- [16] S Walter, MM Glymour, K Koenen, L Liang, ET Tchetgen, M Cornelis, SC Chang, M Rewak, E Rimm, I Kawachi, LD Kubzansky. *Psychological medicine*. **2015**;45(01):181-91.
- [17] GS Yeo. *Molecular and cellular endocrinology*. **2014** Nov 30;397(1):34-41.
- [18] X Zhao, Y Yang, BF Sun, Y Shi, X Yang, W Xiao, YJ Hao, XL Ping, YS Chen, WJ Wang, KX Jin. *Cell research*. **2014** Dec 1;24(12):1403-19.
- [19] YF Chuang, T Tanaka, LL Beason-Held, Y An, A Terracciano, AR Sutin, M Kraut, AB Singleton, SM Resnick, M Thambisetty. *Molecular psychiatry*. **2015** Feb 1;20(1):140-7.
- [20] B Fan, ZQ Du, MF Rothschild. *Animal biotechnology*. **2009** Apr 21;20(2):58-70.
- [21] C Church, S Lee, EA Bagg, JS McTaggart, R Deacon, T Gerken, A Lee, L Moir, J Mecinović, MM Quwailid, CJ Schofield. *PLoS Genet*. **2009** Aug 14;5(8):e1000599.
- [22] D Meyre, K Proulx, H Kawagoe-Takaki, V Vatin, R Gutiérrez-Aguilar, D Lyon, M Ma, H Choquet, F Horber, W Van Hul, L Van Gaal. *Diabetes*. **2010** Jan 1;59(1):311-8.
- [23] J Fischer, L Koch, C Emmerling, J Vierkotten, T Peters, JC Brüning, U Rüther. *Nature*. **2009** Apr 16;458(7240):894-8.